Trinity Biotech (TRIB) Gains from Sales and Divestitures (2021 - 2024)

Trinity Biotech (TRIB) has reported Gains from Sales and Divestitures for 4 consecutive years, with $962000.0 the latest figure, recorded in Q4 2024.

• Quarterly Gains from Sales and Divestitures rose 231.72% year-over-year to $962000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $4.3 million (up 2.05% YoY) and the FY2024 annual result came in at $1.4 million, down 87.32% from the prior year.
• Gains from Sales and Divestitures advanced to $962000.0 in Q4 2024 per TRIB's latest filing, from $290000.0 in the prior quarter.
• Over the last five years, Gains from Sales and Divestitures for TRIB reached as high as $3.0 million in Q4 2022 and fell as low as $519.0 in Q2 2022.
• A 4-year average of $861097.8 and a median of $583000.0 in 2021 frame the typical range for Gains from Sales and Divestitures.
• The largest YoY upside for Gains from Sales and Divestitures was 246.12% in 2022 against a maximum downside of 91.45% in 2022.
• Year by year, Gains from Sales and Divestitures stood at $876000.0 in 2021, then surged by 246.12% to $3.0 million in 2022, then tumbled by 90.44% to $290000.0 in 2023, then soared by 231.72% to $962000.0 in 2024.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $962000.0, $290000.0, and $3.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.